Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Pharmaust Limited ( (AU:NUZ) ) has shared an update.
Neurizon Therapeutics Limited has applied for quotation of 4,182,934 new ordinary fully paid shares on the ASX, with an issue date of 30 April 2026. The additional securities, arising from the exercise or conversion of existing options or other convertible instruments, will expand the company’s quoted capital base and may influence its market liquidity and shareholder structure.
The move signals ongoing capital management activity as Neurizon advances its therapeutic programs within the competitive biotech sector. Investors will watch how the larger free float and potential dilution balance against the company’s funding needs and progress in developing its pharmaceutical pipeline.
The most recent analyst rating on (AU:NUZ) stock is a Buy with a A$0.28 price target. To see the full list of analyst forecasts on Pharmaust Limited stock, see the AU:NUZ Stock Forecast page.
More about Pharmaust Limited
Neurizon Therapeutics Limited, listed on the ASX under the code NUZ, operates in the biotechnology and therapeutics sector. The company focuses on developing pharmaceutical treatments, positioning itself within the broader life sciences and medical innovation market.
Average Trading Volume: 528,579
Technical Sentiment Signal: Sell
Current Market Cap: A$63.08M
See more data about NUZ stock on TipRanks’ Stock Analysis page.